Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release
Yoshinari Obata, … , Norikazu Maeda, Iichiro Shimomura
Yoshinari Obata, … , Norikazu Maeda, Iichiro Shimomura
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e99680. https://doi.org/10.1172/jci.insight.99680.
View: Text | PDF
Research Article Cell biology Metabolism

Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release

  • Text
  • PDF
Abstract

Adiponectin, an adipocyte-derived circulating protein, accumulates in vasculature, heart, and skeletal muscles through interaction with a unique glycosylphosphatidylinositol-anchored cadherin, T-cadherin. Recent studies have demonstrated that such accumulation is essential for adiponectin-mediated cardiovascular protection. Here, we demonstrate that the adiponectin/T-cadherin system enhances exosome biogenesis and secretion, leading to the decrease of cellular ceramides. Adiponectin accumulated inside multivesicular bodies, the site of exosome generation, in cultured cells and in vivo aorta, and also in exosomes in conditioned media and in blood, together with T-cadherin. The systemic level of exosomes in blood was significantly affected by adiponectin or T-cadherin in vivo. Adiponectin increased exosome biogenesis from the cells, dependently on T-cadherin, but not on AdipoR1 or AdipoR2. Such enhancement of exosome release accompanied the reduction of cellular ceramides through ceramide efflux in exosomes. Consistently, the ceramide reduction by adiponectin was found in aortas of WT mice treated with angiotensin II, but not in T-cadherin–knockout mice. Our findings provide insights into adiponectin/T-cadherin–mediated organ protection through exosome biogenesis and secretion.

Authors

Yoshinari Obata, Shunbun Kita, Yoshihisa Koyama, Shiro Fukuda, Hiroaki Takeda, Masatomo Takahashi, Yuya Fujishima, Hirofumi Nagao, Shigeki Masuda, Yoshimitsu Tanaka, Yuto Nakamura, Hitoshi Nishizawa, Tohru Funahashi, Barbara Ranscht, Yoshihiro Izumi, Takeshi Bamba, Eiichiro Fukusaki, Rikinari Hanayama, Shoichi Shimada, Norikazu Maeda, Iichiro Shimomura

×

Figure 3

Adiponectin (APN) affects systemic exosome level in vivo in mouse.

Options: View larger image (or click on image) Download as PowerPoint
Adiponectin (APN) affects systemic exosome level in vivo in mouse.
(A–C,...
(A–C, left panels) Western blots of MFG-E8 and syntenin associated with exosome pellets isolated from plasma of (A) Adipoq (APN) null, heterozygous, and WT littermates; (B) Cdh13 (T-cadherin) null, heterozygous, and WT littermates; and (C) WT mice 4 days after injection of adenovirus expressing APN (Ad-APN) or β-galactosidase (Ad-βGal). (A and B, right panels) Exosomal MFG-E8 and syntenin levels from Western blots. *P < 0.05, **P < 0.01 versus littermate WT mice (1-way ANOVA with Tukey’s post hoc test). (C, right panel) Exosomal MFG-E8 and syntenin levels from Western blot. *P < 0.05, **P < 0.01 versus WT + Ad-βGal (unpaired t test). Data are the mean ± SEM. Plasma APN concentrations were as follows: (A) WT 15.0 ± 1.7 μg/ml, heterozygous 5.0 ± 0.5 μg/ml, homozygous 0.0 ± 0.0 μg/ml; (B) WT 16.3 ± 0.6 μg/ml, heterozygous 28.4 ± 2.5 μg/ml, homozygous 44.0 ± 2.1 μg/ml; (C) Ad-APN 391.4 ± 62.4 μg/ml, Ad-βGal 21.4 ± 2.2 μg/ml.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts